PainReform Ltd. (PRFX)

0.8392 -0.0178 (-2.08%) At close: 04:00PM EDT

PainReform Ltd.

65 Yigal Alon St.
Tel Aviv 6744316
Israel
972 3 7177050
https://www.painreform.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 7

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Ehud Geller Ph.D.	Executive Chairman	150k	N/A	N/A
Mr. Ilan Hadar M.B.A.	CEO & CFO	404k	N/A	1969
Dr. Sigal Aviel	Chief Operating Officer	345k	N/A	1964
Prof. Eli Hazum Ph.D.	CTO & Director	144k	N/A	N/A
Ms. Rita Keynan	Vice President of Pharmaceutical Operations	302k	N/A	1969
Dr. Stephen A. Cooper D.M.D Ph.D.	Executive Vice President of Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

Corporate governance

PainReform Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.